^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
Published date:
06/26/2023
Excerpt:
Phase Ib/II TLP trial (NCT03054363) enrolled patients with HR+/HER2+ MBC treated with ≥2 HER2-targeted agents....Overall response rate was 44.5%, median duration of response was 13.9 months, clinical benefit rate was 70.4%; 60% of patients were on treatment for ≥6 months, 25% for ≥1 year, and 10% for ≥2 years.
Secondary therapy:
letrozole
DOI:
https://doi.org/10.1158/1078-0432.CCR-23-0117
Trial ID:
Source:
Title:
PS10-03 Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer
Published date:
11/17/2020
Excerpt:
The combination of tucatinib with letrozole and palbociclib showed a tolerable and manageable safety profile and evidence of considerable anti-tumor activity that warrant further clinical investigation in pts with HR+/HER2+ MBC.
Secondary therapy:
letrozole
